SCHEMBL3220718

SCHEMBL3220718

COC(=O)c1cc(OC)c(CN2CCN(CC(=O)OC(C)(C)C)CCN(Cc3c(OC)cc(C(=O)OC)cc3OC)CCN(Cc3c(OC)cc(C(=O)OC)cc3OC)CC2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
SLC29A1 Q99808 4/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 2/20 0.39
MAPT P10636 2/20 0.39
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
HSD17B10 Q99714 3/20 0.39
USP2 O75604 2/20 0.38
LMNA P02545 3/20 0.37
MAPK1 P28482 3/20 0.37
HTT P42858 2/20 0.37
ABCC4 O15439 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CHRM3 P20309 1/20 0.37
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3209262 0.86 SLC29A1 (0.51) ALDH1A1SLC29A1GAATSHRMAPT
SCHEMBL7445171 0.81 KDM4E (0.52) ALDH1A1SLC29A1GAATSHRSMN1; SMN2
SCHEMBL13427885 0.79 DDR1 (0.48) ALDH1A1SLC29A1TSHRSMN1; SMN2MEN1
Bromide SCHEMBL3217532 0.78 DDR1 (0.47) ALDH1A1SLC29A1TSHRSMN1; SMN2MEN1
SCHEMBL15693171 0.74 HRH3 (0.41) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL3229628 0.73 CA12 (0.53) ALDH1A1SLC29A1GAATSHRMAPT
SCHEMBL24495622 0.73 ALDH1A1 (0.48) ALDH1A1GAATSHRMAPTTP53
SCHEMBL29831941 0.73 ALDH1A1 (0.48) ALDH1A1GAATSHRMAPTTP53
SCHEMBL6450457 0.73 CHRM2 (0.38) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL3799622 0.72 PLA2G10 (0.41) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100055043-A1 Poly-Halo Metal X-ray Contrast Agents MALLINCKRODT INC. 2010-03-04 US disclosed
EP-2089063-A2 X-RAY CONTRAST AGENTS COMPRISING A METAL CHELATE AND A POLYHALOGENATED PHENOL, THIOPHENOL, RESORCINOL, THIORESORCINOL OR DITHIORESORCINOL Mallinckrodt Inc. (US) 2009-08-19 EP disclosed
WO-2008060399-A2 X-RAY CONTRAST AGENTS COMPRISING A METAL CHELATE AND A POLYHALOGENATED PHENOL, THIOPHENOL, RESORCINOL, THIORESORCINOL OR DITHIORESORCINOL MALLINCKRODT INC. (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100055043-A1 Poly-Halo Metal X-ray Contrast Agents SLC39A3, ZNF277, TPR ALDH1A1 3268/4885SLC29A1 1338/4885GAA 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.